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The goal of the study was to estimate the efficacy of growth hormone (GH) co-treatment to the 
antagonist protocol in IVF/ ICSI cycles in poor responders. A prospective observational study 
involved 75 patients. All patients underwent standard antagonist protocol with or without GH 
co-treatment. GH additional was given a daily subcutaneous injection of 1.33 mg (equivalent 
to 4 IU) of GH from day 1 of ovarian stimulation until the day of human chorionic gonado-
tropin (hCG). Concentrations of GH, insulin-like growth factor I (IGF-I) and IGF binding 
protein-3 (IGFBP-3) in serum and follicular fluid were analyzed. The GH co-treatment sig-
nificantly lowered effective dose of gonadotropins, duration of stimulation, IGFBP-3 level in 
serum and follicular fluid day of oocytes retrieval. The number of oocytes recovered, meta-
phase II stage (MII) oocytes, 2 pronucleus (2 pn) zygote, good-quality transferred embryos 
were significantly higher in the GH+ group. Only patients GH+ group became pregnant. Posi-
tive correlation was found between IGF-I level in follicular fluid, dynamics of IGFBP-3 level 
changes during stimulation protocol and number of good-quality transferred embryos in the 
GH+ group. GH administration in IVF/ICSI cycles for poor responders raises ovarian sensi-
tivity to the gonadotropin exogenous influence, this way, increasing number of high-quality 
embryos and the probability of pregnancy. 
Keywords: growth hormone, poor ovarian response, in vitro fertilization (IVF), assisted repro-
ductive technologies (ART).
Introduction
The prognosis for treatment by IVF is highly dependent upon ovarian response and 
the quality of oocytes retrieved, with both factors deciding the number of good quality 
embryos that will generated. Poor  response  to ovarian stimulation (POR) is not a rare 
event in assisted reproduction (ART); its reported frequency in IVF cycles varies from 9 
to 30 % between investigators [1]. 
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POR remains a problem in IVF cycles until today. Despite the use of different treat-
ment strategies, clinical pregnancy rate is low in poor responders. It often leads to couples 
giving up the treatment or using oocyte donation. There are numerous strategies that have 
been proposed to improve the outcome in the poor responder women despite their lim-
ited successes. Meta-analysis by Kyrou et al. [2] suggested that, out of all of the recently 
proposed protocol alterations, GH addition significantly increased the IVF success rate.
In this research, we aimed to estimate the efficacy of GH co-treatment to the antago-
nist protocol in IVF/ ICSI cycles in poor responders.
Methods
A prospective observational study was performed at ART department of FSBSI 
D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, St. Petersburg, 
Russian Federation between September 2015 and January 2017.
The research included 75 women with POR. Poor responders were defined by the Bo-
logna consensus criteria [1]. At least two of the following three features must be present:
1. The risk factors for POR are represented by maternal age ≥ 40 years and by all the 
known genetic or acquired conditions possibly linked to a reduced amount of 
resting follicles;
2. A POR is represented by a cycle cancelled (following the development of less than 
three growing follicles) or the collection of less than four oocytes in response to 
an ovarian stimulation protocol of at least 150 IU follicle-stimulating hormone 
(FSH) per day;
3. An abnormal ovarian reserve test (i.e. antral follicle count, 5–7 follicles or anti-
Müllerian hormone (AMH), 0.5–1.1 ng/ml).
Two episodes of POR after maximal stimulation are sufficient to definea patient as 
poor responder in the absence of advanced maternal age or abnormal ovarian reserve test.
Exclusion criteria for the research were a day 3  FSH > 20  IU/l, body mass index 
(BMI) ≥ 35 kg/m2 and severe male factor infertility. Written informed consent was ob-
tained from all the couples before IVF treatment.
Study population was divided to two groups. 35 patients were allocated to GH co-
treatment group (GH+ group), the other 40 were allocated to standard antagonist proto-
col without GH administration (GH- group).
All patients underwent gonadotropin releasing hormone (GnRH) antagonist con-
ventional ovarian stimulation with recombinant or menopausal gonadotropins. GH co-
treatment was given a daily subcutaneous injection of 1.33 mg (equivalent to 4 IU) of GH 
(Norditropin pen, Novo Nordisk, Denmark) from day 1 of ovarian stimulation until the 
day of hCG (Fig. 1). 
Baseline serum concentrations of gonadotropins and ovarian hormones (estradiol 
(E2), prolactin (Prol), AMH, FSH and luteinizing hormone (LH)) were measured on day 
3 of pretreatment cycle.
The serum GH, IGF-I and IGFBP-3 levels were analyzed on day 1 of ovarian stimula-
tion and day of oocytes retrieval. Submitted markers were also determined in follicular 
fluid. Follicular fluid was obtained from during oocyte pick up; only samples not con-
taminated with blood and which didn’t contain cumulus-oocyte-complexes were used for 
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the analysis. GH, IGF-I and IGFBP-3 concentrations in serum and follicular fluid were 
measured by enzyme immunoassay (ELISA) (Mediagnost, Germany).
Statistical analysis was performed using the application package “STATISTICA v 
10.0 for Windows” (Statsoft Inc., USA). Data were examined by non-parametric analysis. 
Median and quartiles (Me(LQ;UQ)) of distribution were determined for each continuous 
variable. Hormonal and cycle characteristics were compared by using the Mann-Whitney 
U test, the Wilcoxon test where appropriate. Non-parametric ANOVA was used to com-
pare concentration of GH, IGF-I and IGFBP-3 in serum and follicular fluid. Association 
between two variables was estimated using Spearman correlation coefficient and gamma 
correlation coefficient. The significance level (p) was set at 0.05 for all statistical tests.
Results
Patients in the two groups did not differ significantly in age and gynecological back-
ground (Table 1). The baseline FSH level was significantly higher and the AMH level was 
significantly lower in the GH co-treatment cycle (Table 2). There were no significant dif-
ferences in the serum GH, IGF-I and IGFBP-3 concentrations between the two groups 
(Fig. 2–4). 
The GH concentration in follicular fluid and serum on the day of oocytes retrieval 
was significantly higher (Fig. 2) and IGFBP-3 level in this biological fluids was significant-
ly lower (Fig. 4) in the GH+ group as compared with the GH- group. Moreover, IGF-I level 
in serum on the day of oocytes retrieval was significantly higher in the GH co-treatment 
cycle (Fig. 3).
Fig. 1. Ovulation stimulation protocol
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Table 1. Structure of gynecological diseases
Characteristic
GH+ group, n = 35 GH- group, n = 40
Χ2 p-value
Abs.  % Abs.  %
Endometriosis
I st. – – – – – –
II st. 5 14,29 5 12,5 1,418 >
III st. 1 2,86 3 7,5 0,576 >
IV st. 11 31,43 7 17,5 0,212 >
Adenomyosis 6 20 5 12,5 0,058 >
Myoma 8 22,86 5 12,5 0,768 >
Ovarian dysfunction 31 88,57 32 80 0,3605 >
Chronic salpingo-oophoritis 20 57,14 32 80 3,575 >
Table 2. Hormonal characteristics
Characteristic




Ме LQ UQ Ме LQ UQ
FSH, IU/l 12,5 9,2 14,9 7,15 5,81 8,295 188 0,000001
LH, IU/l 5,7 3,55 7,25 4,535 3,575 5,61 672,5 0,774115
AMH, ng/ml 0,32 0,21 0,5 0,75 0,655 0,85 648,5 0,588066
E2, pg/ml 138 103 187 142,6 100,25 181 95,5 0,254103
Prol, mME/ml 324 245,36 369,23 291,6 257,9 348,91 113,5 0,648383
Fig. 2. Level GH in serum and follicular fluid
136 Вестник СПбГУ. Медицина. 2019. Т. 14. Вып. 2
The serum GH concentration was significantly increased on the day of oocytes re-
trieval than on the first day of stimulation protocol (W = 21, p = 0.015) in the GH+ group. 
Additionally, IGFBP-3  level was significantly diminished in follicular fluid (W = 24, 
p = 0.023) and serum on the day of oocytes retrieval (W = 10, p = 0.003) than on the first 
day of stimulation protocol in the GH+ group. 
Total dosе of gonadotropins was not different between the two groups. However, ef-
fective dose of gonadotropins, duration of stimulation were significantly lower in the GH+ 
Fig. 4. Level IGFBP-3 in serum and follicular fluid
Fig. 3. Level IGF-I in serum and follicular fluid
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group as compared with the GH- group. The number of follicles on the day of hCG, oo-
cytes retrieved, MII oocytes, 2 pn zygote, good-quality transferred embryos were signifi-
cantly higher in the GH+ group as compared with the GH- group (Table 3). 
Table 3. Cycle characteristics
Characteristic




Ме LQ UQ Ме LQ UQ
Starting dose of 
gonadotropins, IU 300 225 300 300 237,5 300 428,5 0,1987
Total dosе of 
gonadotropins, IU 2250 1800 3000 2543,75 1850 3425 226 1,0
Effective dose of 
gonadotropins, IU 750 500 1325 1321,88 712,5 2100 578,5 0,008
Duration of 
stimulation, days 8 7 10 9 8 10 27,5 0,0004
No. of follicles on 
the day of hCG 4 3 7 3 2 4 209,5 0,045
No. of oocytes 
recovered 3 2 5 2 1 3 317 0,0005
No. of MII oocytes 4 3 6 1 0 2 292,5 0,043
No. of 2р zygote 2 1 4 1 0 2 195 0,0004
Day 3 from fertilization
No. of transferred 




2 1 2 1 0 1 6 0,0004
Day 4 from fertilization
No. of transferred 




2 1 2 0 0 0 0 0,0489
Positive correlation was found between IGF-I level in follicular fluid and number of 
good-quality transferred embryos (γ = 0.5, р = 0.048); dynamics of IGFBP-3 level chang-
es in follicular fluid and serum on the first day of stimulation protocol and number of 
oocytes retrieved (γ = 0.53, р = 0.007), number of fertilyzed oocytes (R = 0.66, p = 0.005), 
number of good-quality transferred embryos (γ = 0.72, р = 0.004) in the GH+ group. 
Two patients in the GH+ group and seventeen patients in the GH- group didn’t reach 
embryo transfer stage, but cycle cancellation rate was significantly higher in the GH- 
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group (Fisher’s exact test 0.01; p < 0.05). The reasons for cancellation in the GH- group 
were absence of cumulus-oocyte-complexes retrieved in five patients, total fertilization 
failure in eleven patients, and no-cleavage in one patient.
Only patients GH+ group became pregnant; clinical pregnancy rate was 24.24 %. 
Probability of pregnancy was significantly increased in the GH+ group as compared with 
the GH- group (OR (95 %CI) = 9.1 (1.034–80.093), р < 0.05).
No side effect was seen in any of the patients.
Discussion
Over 25 years ago, Owen et al. [3] concluded that GH co-treatment improves the 
ovarian response to ordinary ovarian stimulation protocols in sub-optimal responders. 
This conclusion was supported studies by Homburg et al. [4] demonstrating that GH ad-
ministration raises ovarian sensitivity to the gonadotropins influence. GH mRNA and 
immunoreactivity are discovered in ovarian stromal and follicular tissue from human 
[5]. GH gene expression is initiated early in follicular development in humans, since GH 
mRNA and immunoreactivity were found in the oocyte cytoplasm and the granulosa cells 
of fetal primordial follicles [6]. In this research, effective dose of gonadotropins, duration 
of stimulation were significantly lower in the GH co-treatment. Furthermore, a study by 
Kucuk et al. [7] observed an improved ovarian response as well as increased ART success. 
Despite numerous more recent studies, the GH co-treatment in IVF/ICSI cycles for 
poor responders remains controversial [8]. The problem is supposed to associate with the 
definition of a poor responder, underpowered statistical analysis, the pooling of patients 
with diverse risk factors such as age, and heterogeneous protocols of GH administration, 
ovarian stimulation, and luteal support [9]. However, most studies conclude that the out-
comes improved by GH are generally those reflecting increased oocyte quality, such as 
the number of MII stage recovered, the fertilization rate [7], the number of embryos 
reaching the transfer stage [9], the pregnancy rate [10] and the rate of live births [11]. 
This research showed that GH co-treatment to the antagonist protocol in poor respond-
ers undergoing IVF/ICSI cycles significantly improved the number of oocytes collected, 
MII oocytes retrieved, 2 pn zygote and good-quality transferred embryos. Moreover, ad-
juvant GH therapy seems to enhance both the fertilization rate and the quality of the 
resulting embryos, as indicated by improved blastomere uniformity and cleavage rate 
and decreased apoptosis [12].
GH is reported to modulate the action of FSH on granulosa cells by up-regulating the 
local synthesis of insulin-like growth factor-I. The IGF-I amplifies the effect of gonado-
tropin action at the level of both the granulosa and theca cell [13; 14]. It was found, that 
follicular GH levels were positively correlated with IVF success [15], and follicles contain-
ing higher GH levels gave rise to the highest quality embryos [16]. In this study, positive 
correlation was found between IGF-I level in follicular fluid and number of good-quality 
transferred embryos; dynamics of IGFBP-3 level changes in follicular fluid and serum on 
the first day of stimulation protocol and number of oocytes retrieved, number of fertilyzed 
oocytes, number of good-quality transferred embryos in the GH+ group. 
Most systematic reviews and meta-analyzes suggested that GH addition significantly 
increased clinical pregnancy rate and live birth rates [8; 9; 11]. In this study, probability of 
pregnancy was significantly increased in the GH+ group as compared with the GH- group.
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Potential side-effects observed with GH treatment include increased fluid retention, 
resulting in edema, headaches, and/or joint pain, neoplasms, cerebrovascular events, and 
altered glucose metabolism [17]. However, GH co-treatment in IVF/ ICSI cycles is not as-
sociated with any adverse events except for slight edema. In this study, no side effect was 
seen in any of the patients.
In conclusion, GH administration in IVF/ICSI cycles for poor responders raises ovar-
ian sensitivity to the gonadotropin exogenous influence, this way, increasing number of 
oocytes collected, MII oocytes retrieved, fertilization rate, number of high-quality embry-
os and the probability of pregnancy. The effectiveness of overcoming infertility by IVF in 
patients with POR in terms of adjuvant GH therapy depends on the dynamics of increas-
ing IGF-I concentration and the dynamics of decreasing IGFBP-3 concentration in blood 
serum and follicular fluid during ovarian stimulation. Taking into consideration small 
sample of women examined, it is necessary to continue the study of GH use effectiveness 
and safety for the recommendation of its wide administration in clinical practice. 
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